Project description
Improving nanoparticle-based drug delivery
Recent advances in nanotechnology have paved the way for the use of nanoparticles in cancer therapy as drug delivery vehicles. Despite the advantages of nanoparticle drug delivery, including high selectivity and reduced toxicity, there are various aspects to the process that remain elusive, such as the acquisition of proteins upon in vivo injection. The EU-funded NanoRNA_PC project will employ state-of-the-art methodologies to characterise the protein corona formed on RNA nanoparticles upon interaction with biological components. Understanding the composition of the protein corona on nanoparticles is expected to improve their design as well as their biological outcome.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF-EF-SE - Society and Enterprise panel
Coordinator
W12 0BZ London
United Kingdom
See on map